SOM0226 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
28全身性アミロイドーシス2

28. 全身性アミロイドーシス


臨床試験数 : 267 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-001586-27-ES
(EUCTR)
25/07/201402/06/2014Study of SOM0226 in familial amyloid polyneuropathy (FAP) patients and asymptomatic carriers to evaluate protein stabilization activityStudy of SOM0226 in familial amyloid polyneuropathy (FAP) patients and asymptomatic carriers to evaluate protein stabilization activity Patients with familial amyloid polyneuropathy (FAP), asymptomatic carriers and healthy volunteers
MedDRA version: 17.0;Level: LLT;Classification code 10057949;Term: Familial amyloid polyneuropathy;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Tasmar
INN or Proposed INN: TOLCAPONE
SOM Innovation Biotech SL (SOM Biotech)NULLNot RecruitingFemale: yes
Male: yes
Spain
2NCT02191826
(ClinicalTrials.gov)
July 20149/7/2014Study of SOM0226 in Familial Amyloid PolyneuropathyStudy of SOM0226 in Familial Amyloid Polyneuropathy (FAP) Patients and Asymptomatic Carriers to Evaluate Protein Stabilization ActivityFamilial Amyloid Polyneuropathy (FAP)Drug: SOM0226SOM Biotech SLHospital Vall d'HebronCompleted18 YearsN/ABoth17Phase 1/Phase 2Spain